# BP2301

Source: https://onco.cc/drugs/bp2301/  
OnCo record `bp2301` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BP2301 is an experimental autologous CAR-T cell therapy from BrightPath Biotherapeutics, in phase 1 trials for bone and soft tissue sarcoma and gynaecological cancers.

## Summary

BP2301 is an autologous CAR-T cell therapy (non-viral gene transfer) from BrightPath Biotherapeutics. An autologous HER2-targeted CAR-T cell therapy made with non-viral gene transfer for HER2-expressing solid tumours. Its furthest stage is phase 1, for bone and soft tissue sarcoma and gynaecological cancers. No clinical trial naming it is registered on ClinicalTrials.gov. Company page says a phase 1 trial started in relapsed/advanced bone and soft tissue sarcoma and gynaecological cancers; no ClinicalTrials.gov entry found for BP2301 (likely a Japanese registry). It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline
- Code: BP2301
- Modality: Autologous CAR-T cell therapy (non-viral gene transfer)
- Mechanism: An autologous HER2-targeted CAR-T cell therapy made with non-viral gene transfer for HER2-expressing solid tumours.

## Sources

- BrightPath Biotherapeutics: brightpathbio.com: https://www.brightpathbio.com/pipeline/bp2301.html

## Connected records

- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [BrightPath Biotherapeutics](https://onco.cc/companies/brightpath-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/bp2301.json